CClinicalTrials.gg
RecruitingNCT07602452Updated May 22, 2026

Bilateral Erector Spinae Plane Block Versus Bilateral Oblique Subcostal Transversus Abdominis Plane Block for Postoperative Analgesia in Colorectal Surgery

An interventional study of Erector Spinae Plane Block and Oblique Subcostal Transversus Abdominis Plane Block in Bilateral Erector Spinae Plane Block, Bilateral Oblique Subcostal Transversus Abdominis Plane Block and Postoperative Analgesia, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to compare the ultrasound-guided bilateral erector spinae plane block (ESPB) and oblique subcostal transverse abdominal plane block (OSTAPB) for postoperative analgesia in colorectal surgery.

Read the detailed description

Colorectal surgery remains the therapeutic cornerstone for the management of a wide variety of gastrointestinal disorders encompassing malignancies and inflammatory conditions.

Oblique subcostal transverse abdominal plane block (OSTAPB) is a regional block technique that involves injecting local anesthetics between the transverse abdominal muscle plane and the internal oblique abdominal muscle plane.

Ultrasound-guided erector spinae plane block (ESPB) is a novel technique that specifically targets the ventral rami, dorsal rami, and rami communicantes of the spinal nerves. Local anesthetic agents were observed to extend cranially and caudally over numerous dermatomal levels following injection.

02

Conditions studied

  • Bilateral Erector Spinae Plane Block
  • Bilateral Oblique Subcostal Transversus Abdominis Plane Block
  • Postoperative Analgesia
  • Colorectal Surgery
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 to 75 years old.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status II-III.
  • Scheduled for open colorectal surgery under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • History of opioid abuse.
  • Chronic opioid consumption.
  • Body mass index (BMI) ≥ 35 kg/m2.
  • Severe cardiac insufficiency, defined as New York Heart Association (NYHA) class III or IV heart failure.
  • Renal failure, defined as an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m².
  • Hepatic encephalopathy.
  • Having a skin infection at or near the puncture site.
  • Coagulopathy, defined as platelet count \< 100,000/mm³, INR > 1.5, or use of anticoagulant therapy that could not be withheld.
  • Allergy to drugs used in the study.
  • History of previous or recurrent laparoscopic cholecystectomy procedures.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Group I

    Patients will receive ultrasound-guided erector spinae plane block.

    Other: Erector Spinae Plane Block

  • Experimental
    Group II

    Patients will receive ultrasound-guided oblique subcostal transversus abdominis plane block.

    Other: Oblique Subcostal Transversus Abdominis Plane Block

Interventions

  • OtherErector Spinae Plane Block

    Patients will receive ultrasound-guided erector spinae plane block.

  • OtherOblique Subcostal Transversus Abdominis Plane Block

    Patients will receive ultrasound-guided oblique subcostal transversus abdominis plane block.

06

What researchers measure

Primary outcomes

  1. Degree of pain

    Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS). NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at 0, 2, 4, 6, 12, and 24 h postoperatively.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Time to the first rescue analgesia

    Time to the first request for the rescue analgesia will be recorded from end of surgery to first dose of morphine administrated.

    Time frame: 24 hours postoperatively

  2. Intraoperative fentanyl consumption

    Additional fentanyl bolus dosages of 1 µg/kg IV will be administered if heart rate or mean arterial blood pressure elevated more than 20% of the baseline (after exclusion of other causes than pain).

    Time frame: Intraoperatively

  3. Total morphine consumption

    Rescue analgesia of morphine will be given as 3 mg bolus (maximum dose of 0.5 mg/kg/24hours) if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.

    Time frame: 24 hours postoperatively

  4. Mean arterial pressure

    Mean arterial pressure will be recorded at: * T0: Baseline reading preoperatively (in the preoperative holding area). * T1: Immediately before intubation. * T2: 15 minutes after intubation. * T3: 30 minutes after intubation. * T4: 45 minutes after intubation. * T5: 60 minutes after intubation. * T6: At the end of surgery.

    Time frame: Till end of surgery (Up to 2 hours)

  5. Heart rate

    Heart rate will be recorded at: * T0: Baseline reading preoperatively (in the preoperative holding area). * T1: Immediately before intubation. * T2: 15 minutes after intubation. * T3: 30 minutes after intubation. * T4: 45 minutes after intubation. * T5: 60 minutes after intubation. * T6: At the end of surgery.

    Time frame: Till end of surgery (Up to 2 hours)

  6. Degree of patient satisfaction

    Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).

    Time frame: 24 hours postoperatively

  7. Quality of Recovery

    Quality of Recovery (QOR- 15) scale will be recorded at 24 hours after surgery. Each item on the QoR-15 scale is scored from 0 (unfavourable) to 10 (favourable), resulting in an aggregate score from 0 (no recovery) to 150 (total recovery).

    Time frame: 24 hours postoperatively

  8. Incidence of adverse events

    Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication will be recorded.

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Cairo University
    Cairo, 12613, Egypt
    • Mohammed M Alarousy, MSc · Contact · mohammedalarousy0@gmail.com · 00201149404478
    • Dina Z Khalaf, MD · Sub investigator
    • Tamer K Khair, MD · Sub investigator
    • Shady R Mikhail, MD · Sub investigator
    • Michael W Halim, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07602452
Lead sponsor
Cairo University
Responsible party
Mohammed Mahmoud Mohammed Alarousy (Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Management, Cairo University, Tanta, Egypt., Cairo University) — Principal investigator
First posted
May 22, 2026
Start date
May 21, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Mohammed M Alarousy, MSc
Contact
mohammedalarousy0@gmail.com
00201149404478

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion